264 related articles for article (PubMed ID: 18586917)
1. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Dahabreh IJ; Linardou H; Siannis F; Fountzilas G; Murray S
Oncologist; 2008 Jun; 13(6):620-30. PubMed ID: 18586917
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.
Viani GA; Afonso SL; Stefano EJ; De Fendi LI; Soares FV
BMC Cancer; 2007 Aug; 7():153. PubMed ID: 17686164
[TBL] [Abstract][Full Text] [Related]
4. Risk of Congestive Heart Failure in Early Breast Cancer Patients Undergoing Adjuvant Treatment With Trastuzumab: A Meta-Analysis.
Long HD; Lin YE; Zhang JJ; Zhong WZ; Zheng RN
Oncologist; 2016 May; 21(5):547-54. PubMed ID: 27026675
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials.
Yin W; Jiang Y; Shen Z; Shao Z; Lu J
PLoS One; 2011; 6(6):e21030. PubMed ID: 21695277
[TBL] [Abstract][Full Text] [Related]
6. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
Gianni L; Dafni U; Gelber RD; Azambuja E; Muehlbauer S; Goldhirsch A; Untch M; Smith I; Baselga J; Jackisch C; Cameron D; Mano M; Pedrini JL; Veronesi A; Mendiola C; Pluzanska A; Semiglazov V; Vrdoljak E; Eckart MJ; Shen Z; Skiadopoulos G; Procter M; Pritchard KI; Piccart-Gebhart MJ; Bell R;
Lancet Oncol; 2011 Mar; 12(3):236-44. PubMed ID: 21354370
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
[TBL] [Abstract][Full Text] [Related]
8. Role of trastuzumab in adjuvant therapy for locally invasive breast cancer.
Kabe KL; Kolesar JM
Am J Health Syst Pharm; 2006 Mar; 63(6):527-33. PubMed ID: 16522889
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
Liberato NL; Marchetti M; Barosi G
J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review.
Madarnas Y; Trudeau M; Franek JA; McCready D; Pritchard KI; Messersmith H
Cancer Treat Rev; 2008 Oct; 34(6):539-57. PubMed ID: 18502589
[TBL] [Abstract][Full Text] [Related]
12. Use of trastuzumab for the treatment of early stage breast cancer.
Braga S; dal Lago L; Bernard C; Cardoso F; Piccart M
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1153-64. PubMed ID: 16925482
[TBL] [Abstract][Full Text] [Related]
13. For or against adjuvant trastuzumab for pT1a-bN0M0 breast cancer patients with HER2-positive tumors: a meta-analysis of published literatures.
Zhou Q; Yin W; Du Y; Lu J
PLoS One; 2014; 9(1):e83646. PubMed ID: 24392090
[TBL] [Abstract][Full Text] [Related]
14. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Tubiana-Mathieu N; Cany L; Catala S; Khayat D; Pauporté I; Kramar A;
Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
Tolaney SM; Barry WT; Dang CT; Yardley DA; Moy B; Marcom PK; Albain KS; Rugo HS; Ellis M; Shapira I; Wolff AC; Carey LA; Overmoyer BA; Partridge AH; Guo H; Hudis CA; Krop IE; Burstein HJ; Winer EP
N Engl J Med; 2015 Jan; 372(2):134-41. PubMed ID: 25564897
[TBL] [Abstract][Full Text] [Related]
16. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
Mallmann P
Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
[No Abstract] [Full Text] [Related]
17. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
18. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.
Olson EM; Abdel-Rasoul M; Maly J; Wu CS; Lin NU; Shapiro CL
Ann Oncol; 2013 Jun; 24(6):1526-33. PubMed ID: 23463626
[TBL] [Abstract][Full Text] [Related]
19. The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis.
Wang Y; Liu Y; Du Y; Yin W; Lu J
Curr Med Res Opin; 2013 Jun; 29(6):633-42. PubMed ID: 23574264
[TBL] [Abstract][Full Text] [Related]
20. Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials.
Gyawali B; Niraula S
Cancer Treat Rev; 2017 Nov; 60():18-23. PubMed ID: 28863313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]